Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions.

Identifying mechanisms to enhance neuroprotection holds tremendous promise in developing new treatments for neuropsychiatric and neurodegenerative diseases. We sought to determine the potential role for microRNAs (miRNAs) in neuroprotection following neuronal death. A neuronal culture system of rat cerebellar granule cells was used to examine miRNA expression changes following glutamate-induced excitotoxicity and neuroprotective treatments. Combination treatment with the mood stabilizers lithium and valproic acid provided near-complete protection from glutamate excitotoxicity. Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182, miR-222, miR-495, and miR-690. We then verified the apoptotic actions of miR-34a mimic in a human neuroblastoma cell line (SH-SY5Y) under basal conditions and following endoplasmic reticulum stress. To gain insight into the function of these mood stabilizer-regulated miRNAs, we performed two separate analyses: a candidate approach using Ingenuity Pathway Analysis that was restricted to only our PCR-verified miRNAs, and a global approach using DIANA-mirPath that included all significantly regulated miRNAs. It was observed that the pathways associated with mood stabilizer-regulated miRNAs in our study (global approach) are strongly associated with pathways implicated in neuropsychiatric diseases such as schizophrenia. We also observed an overlap in the mood stabilizer-regulated miRNAs identified from our study along with dysregulated miRNAs in both neuropsychiatric and neurodegenerative disorders. We anticipate that these associations and overlaps implicate critical pathways and miRNAs in disease mechanisms for novel therapeutic treatments that may hold potential for many neurological diseases.

[1]  Fuad G. Gwadry,et al.  Gene and miRNA expression profiles in autism spectrum disorders , 2011, Brain Research.

[2]  J. Barker,et al.  Development of an Ischemic Tolerance Model in a PC12 Cell Line , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  D. Chuang,et al.  Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease , 2011, Neuropsychopharmacology.

[4]  Takanobu Nakazawa,et al.  Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation , 2002, Journal of neurochemistry.

[5]  Xavier Estivill,et al.  A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing , 2010, Nucleic acids research.

[6]  Z. Marinova,et al.  Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition , 2008, The Journal of Neuroscience.

[7]  D. Chuang,et al.  Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Nikolaos Mellios,et al.  A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. , 2008, Human molecular genetics.

[9]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[10]  Zhumur Ghosh,et al.  A complex crosstalk between polymorphic microRNA target sites and AD prognosis , 2011, RNA biology.

[11]  M. Sinha,et al.  Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. , 2010, Biochemical and biophysical research communications.

[12]  Peng Liu,et al.  miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation , 2009, Brain Research Bulletin.

[13]  A. A. Kan,et al.  Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response , 2012, Cellular and Molecular Life Sciences.

[14]  S. Papson,et al.  “Model” , 1981 .

[15]  M. Gorospe,et al.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. , 2011, Molecular cell.

[16]  D. Geschwind,et al.  Heterogeneous dysregulation of microRNAs across the autism spectrum , 2008, neurogenetics.

[17]  Leilei Gong,et al.  microRNA-222 Targeting PTEN Promotes Neurite Outgrowth from Adult Dorsal Root Ganglion Neurons following Sciatic Nerve Transection , 2012, PloS one.

[18]  Joel S Parker,et al.  microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder , 2007, Genome Biology.

[19]  D. Chuang,et al.  Long Term Lithium Treatment Suppresses p53 and Bax Expression but Increases Bcl-2 Expression , 1999, The Journal of Biological Chemistry.

[20]  Gaofeng Wang,et al.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.

[21]  Guang Chen,et al.  Evidence for Selective microRNAs and Their Effectors as Common Long-Term Targets for the Actions of Mood Stabilizers , 2009, Neuropsychopharmacology.

[22]  H. Manji,et al.  Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines , 2010, Genome Medicine.

[23]  Zhong-Wei Sun 孙中伟,et al.  Excitotoxicity effects of glutamate on human neuroblastoma SH-SY5Y cells via oxidative damage , 2010, Neuroscience Bulletin.

[24]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[25]  Xavier Estivill,et al.  MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. , 2011, Human molecular genetics.

[26]  J. Roh,et al.  MicroRNAs Induced During Ischemic Preconditioning , 2010, Stroke.

[27]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[28]  L. Tsai,et al.  The Mood Stabilizers Valproic Acid and Lithium Enhance Mesenchymal Stem Cell Migration via Distinct Mechanisms , 2010, Neuropsychopharmacology.

[29]  Peter T. Nelson,et al.  Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter , 2011, Acta Neuropathologica.

[30]  M. Castoldi,et al.  Expression of spinal cord microRNAs in a rat model of chronic neuropathic pain , 2012, Neuroscience Letters.

[31]  Bo Xiao,et al.  MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus , 2012, BMC Neuroscience.

[32]  A. Sawa,et al.  Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons , 2004, The Pharmacogenomics Journal.

[33]  D. Chuang,et al.  Endogenous α-Synuclein Is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity , 2006, The Journal of Neuroscience.

[34]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[35]  Richard David-Rus,et al.  Altered MicroRNA Expression Profiles in Postmortem Brain Samples from Individuals with Schizophrenia and Bipolar Disorder , 2011, Biological Psychiatry.

[36]  H. Geekiyanage,et al.  MicroRNA-137/181c Regulates Serine Palmitoyltransferase and In Turn Amyloid β, Novel Targets in Sporadic Alzheimer's Disease , 2011, The Journal of Neuroscience.

[37]  R. Malenka,et al.  An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration , 2012, Nature Neuroscience.

[38]  J. Hallenbeck,et al.  Global Protein Conjugation by Ubiquitin-Like-Modifiers during Ischemic Stress Is Regulated by MicroRNAs and Confers Robust Tolerance to Ischemia , 2012, PloS one.

[39]  Yogesh K. Dwivedi,et al.  MicroRNA Expression Is Down-Regulated and Reorganized in Prefrontal Cortex of Depressed Suicide Subjects , 2012, PloS one.

[40]  H. Manji,et al.  The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNS , 1999, Journal of neurochemistry.

[41]  E. Abraham,et al.  miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses , 2009, Proceedings of the National Academy of Sciences.

[42]  A. Delacourte,et al.  Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression , 2008, Proceedings of the National Academy of Sciences.

[43]  Michael E. Greenberg,et al.  A brain-specific microRNA regulates dendritic spine development , 2006, Nature.

[44]  Yvonne Tay,et al.  A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes , 2006, Cell.

[45]  V. Perry,et al.  Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[46]  G. Jicha,et al.  Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease , 2012, Experimental Neurology.

[47]  S. Tabrizi,et al.  Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. , 2011, Human molecular genetics.

[48]  Hyman M. Schipper,et al.  MicroRNA Expression in Alzheimer Blood Mononuclear Cells , 2007, Gene regulation and systems biology.

[49]  D. Chuang,et al.  Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model , 2008, Neuroscience.

[50]  S. Hébert,et al.  Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function , 2011, Molecular Neurodegeneration.

[51]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[52]  T. Tuschl,et al.  Identification of Tissue-Specific MicroRNAs from Mouse , 2002, Current Biology.

[53]  H. Hwu,et al.  MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia , 2011, PloS one.

[54]  J. Satoh,et al.  Aberrant microRNA expression in the brains of neurodegenerative diseases: miR‐29a decreased in Alzheimer disease brains targets neurone navigator 3 , 2010, Neuropathology and applied neurobiology.

[55]  Harshini Sarojini,et al.  Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice , 2011, Aging.

[56]  M. Gratacós,et al.  Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. , 2010, Human molecular genetics.

[57]  L. Tsai,et al.  Mesenchymal Stem Cells Primed With Valproate and Lithium Robustly Migrate to Infarcted Regions and Facilitate Recovery in a Stroke Model , 2011, Stroke.

[58]  J. Wendland,et al.  Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling , 2008, Molecular and Cellular Neuroscience.

[59]  Z. Marinova,et al.  Potent neuroprotective effects of novel structural derivatives of valproic acid: Potential roles of HDAC inhibition and HSP70 induction , 2010, Neuroscience Letters.

[60]  E. Martin,et al.  Convergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease , 2011, PloS one.

[61]  Murray J. Cairns,et al.  Upregulation of Dicer and MicroRNA Expression in the Dorsolateral Prefrontal Cortex Brodmann Area 46 in Schizophrenia , 2011, Biological Psychiatry.

[62]  A. Elkahloun,et al.  Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. , 2012, American journal of translational research.

[63]  N. Bhattacharyya,et al.  Regulation of miR-146a by RelA/NFkB and p53 in STHdhQ111/HdhQ111 Cells, a Cell Model of Huntington's Disease , 2011, PloS one.

[64]  M. Cairns,et al.  Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. , 2008, Human molecular genetics.

[65]  Yadong Wang,et al.  miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..

[66]  M. Cairns,et al.  Schizophrenia is associated with an increase in cortical microRNA biogenesis , 2009, Molecular Psychiatry.

[67]  Á. Dobolyi,et al.  The Neuroprotective Functions of Transforming Growth Factor Beta Proteins , 2012, International journal of molecular sciences.